Neuralstem Inc. Daily Stock Analysis

Daily Stock Analysis, CUR, Neuralstem Inc, priceseries

Neuralstem Inc. Daily Stock Analysis
Stock Information
Open
1.71
Close
1.52
High
1.81
Low
1.48
Previous Close
1.09
Daily Price Gain
0.43
YTD High
13.70
YTD High Date
Mar 20, 2019
YTD Low
1.07
YTD Low Date
Nov 7, 2019
YTD Price Change
-5.08
YTD Gain
-76.97%
52 Week High
13.70
52 Week High Date
Mar 20, 2019
52 Week Low
1.07
52 Week Low Date
Nov 7, 2019
52 Week Price Change
-8.68
52 Week Gain
-85.10%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 24. 2017
77.20
Mar 21. 2017
108.43
17 Trading Days
40.46%
Link
LONG
May 31. 2017
89.20
Jun 12. 2017
97.14
8 Trading Days
8.90%
Link
LONG
Jun 21. 2017
107.40
Jul 5. 2017
114.64
9 Trading Days
6.74%
Link
LONG
Jan 17. 2019
7.40
Jan 23. 2019
7.80
3 Trading Days
5.41%
Link
LONG
Feb 13. 2019
9.00
Feb 25. 2019
9.70
7 Trading Days
7.78%
Link
LONG
Apr 17. 2019
8.80
Apr 24. 2019
9.35
4 Trading Days
6.25%
Link
LONG
Jul 16. 2019
7.00
Jul 19. 2019
7.74
3 Trading Days
10.50%
Link
LONG
Oct 15. 2019
1.35
Oct 16. 2019
1.50
1 Trading Days
11.48%
Link
Company Information
Stock Symbol
CUR
Exchange
NasdaqCM
Company URL
http://www.neuralstem.com
Company Phone
301-366-4841
CEO
Richard J. Daly
Headquarters
Maryland
Business Address
20271 GOLDENROD LANE, GERMANTOWN, MD 20876
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001357459
About

Neuralstem, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of central nervous system therapies based on human neuronal stem cells and small molecule compounds. Its patented technology enables the commercial-scale production of central nervous system stem cells. The company was founded by I. Richard Garr, Karl Y. Johe, and Merrill Solomon in 1996 and is headquartered in Germantown, MD.

Description

Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research, development, and commercialization of central nervous system therapies based on its proprietary human neuronal stem cells and stem-cell derived small molecule compounds. The company's stem cell technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its clinical development products include NSI-189, which has completed Phase I clinical trial for the treatment of major depressive disorder, as well as is in Phase I clinical trial for the treatment of other psychiatric and/or cognitive impairment indications associated with hippocampal atrophy; and NSI566 that has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as is in Phase I clinical trials for the treatment of chronic spinal cord injury and motor deficits due to ischemic stroke. The company was founded in 1996 and is headquartered in Germantown, Maryland.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading